One Health

People living with diseases such as cancer, cardiovascular disease, and diabetes are more vulnerable to infections, often requiring treatment with antifungals or antibiotics, which increases the risk of drug-resistant infections. This drug-resistance is also referred to as Antimicrobial Resistance or AMR.
AMR undermines the effectiveness of treatments for secondary infections in those already battling health issues, leading to longer hospital stays, increasing complications, higher healthcare costs and mortality.
Separating AMR and its impact on those with underlying conditions ignores shared patient challenges and creates gaps in patient care leading to poor outcomes for patients.
Upcoming Events:
We are excited to invite you to a powerful global dialogue on the intersection of Antimicrobial Resistance (AMR) and Noncommunicable Diseases (NCDs), hosted by the WHO Taskforce of AMR Survivors.

Bridging the Divide: AMR and NCDs Global Dialogue

  • Date July 24, 2025
  • 14:30–16:00 CEST
Click Here to Register!
This event is a timely call-to-action ahead of the UN High-Level Meeting on NCDs and Mental Health, and will bring together survivors, advocates, and experts to spotlight shared challenges and solutions.
Why this matters:
  • People living with NCDs are more vulnerable to drug-resistant infections
  • AMR and NCDs share systemic drivers such as health inequities and access barriers
  • This is a platform to amplify survivor voices, unite advocacy communities, and shape future global health commitments
We encourage you to register and help us spread the word.